You are here: Industry Insights > AMRI

News List

Curia to Acquire Integrity Bio contractpharma
July 14, 2021
Curia, formerly AMRI, a contract research, development and manufacturing organization, has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish company headquartered in Camarillo, CA.
AMRI Becomes Curia contractpharma
July 13, 2021
Albany Molecular Research, Inc. (AMRI), a global contract research, development and manufacturing organization serving the pharmaceutical and biopharmaceutical industries, is changing its name to Curia, effective July 12, 2021.
AMRI Adds R&D and Mfg. Solutions for Orphan Products contractpharma
May 06, 2021
Albany Molecular Research, Inc. (AMRI), a global provider of contract research, development and manufacturing services, expanded access to its accelerated solutions platform, spanning R&D to manufacturing for orphan and rare disease products.
AMRI Contributes to Efforts to Increase COVID-19 Vax Supply contractpharma
February 26, 2021
Albany Molecular Research, Inc. (AMRI) announced that the company has been chosen to support the development and manufacture of lipid excipients for the Pfizer-BioNTech COVID-19 vaccine.
AMRI Makes Executive Move contractpharma
February 09, 2021
Albany Molecular Research, Inc. (AMRI), a global provider of advanced contract research, development and manufacturing solutions, has appointed Scott Waldman as senior vice president, corporate development.
AMRI Named Exclusive API Supplier for Recently Approved Acne Treatment contractpharma
November 09, 2020
Albany Molecular Research, Inc. (AMRI) has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s recently approved acne treatment, Winlevi (clascoterone) cream 1%.
AMRI to Provide Sterile Fill/Finish Mfg. for AstraZeneca’s COVID-19 Vax contractpharma
September 17, 2020
To supply the vaccine candidate AZD1222 from AMRI’s drug product manufacturing facility in Albuquerque, NM.
AMRI Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine americanpharmaceuticalreview
September 07, 2020
Albany Molecular Research, Inc. (AMRI) has signed a supply agreement with AstraZeneca to support the manufacture of AstraZeneca’s COVID-19 vaccine candidate AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus.
ViralClear, AMRI Enter COVID-19 Partnership contractpharma
July 14, 2020
For the manufacture of merimepodib API in development for the potential treatment of COVID-19.
CDMO pledges increased production of hydroxychloroquine sulfate, potential COVID-19 treatment europeanpharmaceuticalreview
May 08, 2020
The CDMO AMRI has said it will boost its production of the malaria drug hydroxychloroquine sulfate, identified as a potential COVID-19 treatment, following an emergency use authorisation from the FDA.

Previous page 1 2 Next page